Home / Health / New mRNA Cancer Vaccine Shows Promise
New mRNA Cancer Vaccine Shows Promise
25 Aug
Summary
- New personalized vaccine combined with a drug halted skin cancer recurrence in patients.
- The groundbreaking treatment utilizes mRNA technology, similar to some COVID-19 vaccines.
- Significant funding cuts for mRNA vaccine research were made in August 2025.
A significant advancement in cancer treatment has emerged from a recent trial where a new personalized vaccine, administered with a companion drug, effectively stopped skin cancer from returning in participants. This innovative approach leverages mRNA technology, a scientific platform notably recognized for its role in some COVID-19 vaccines.
Despite this medical progress, vaccine technology, particularly mRNA, has faced increasing controversy in the United States. This sentiment has been amplified by vaccine skepticism. As a result, in August 2025, $500 million in funding designated for mRNA vaccine research was cancelled.
This substantial funding reduction affected 22 distinct projects. These initiatives were spearheaded by major pharmaceutical corporations, including Pfizer and Moderna, and focused on developing vaccines for various illnesses such as bird flu and other viral threats, according to the department announcing the cuts.
